Showing 3931-3940 of 4927 results for "".
- Study Highlights Adverse Events Associated with Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/study-highlights-adverse-events-associated-with-energy-based-vaginal-rejuvenation/2460010/Concerns from the federal Food and Drug Administration (FDA) sired the first assessment of adverse events related to device-based procedures marketed for ‘vaginal rejuvenation,’ and the new analysis of the Manufacturer and User Facility Device Experience (MAUDE) database identified a
- FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-duobrii-for-treatment-of-plaque-psoriasis/2460009/The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical lotion that contains a unique combination of halobetasol prop
- Ovation Science Appoints Medical Dermatology Advisory Boardhttps://practicaldermatology.com/news/ovation-science-appoints-medical-dermatology-advisory-board/2460008/Ovation Science, Inc. has entered into an exclusive agreement with Skincareguide.com Ltd., to act as the Company's Medical Dermatology Advisory Board for cannabis formulated products. The objective of the Medical Dermatology Advisory Board is to provide guidance, along with clinical, scientif
- Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapyhttps://practicaldermatology.com/news/fibrocell-to-collaborate-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-rdeb-gene-therapy/2460004/Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disord
- Maine Gets SUNucatedhttps://practicaldermatology.com/news/maine-gets-sunucated/2460001/Maine is joining 19 other states in allowing students to possess and use sunscreen in school. Governor Janet Mills signed LD 441, which was sponsored by Senator Cathy Breen. Modeled after American Society for Dermatologic Surgery Association’s (ASDSA) SUNucate legislation, the bil
- AIM at Melanoma Opens Melanoma Tissue Bank in the UShttps://practicaldermatology.com/news/aim-at-melanoma-opens-melanoma-tissue-bank-in-the-us/2459991/AIM at Melanoma celebrated the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center. The Pittsburgh site is one of six global locations of the consortium. These six institutions
- Meet JOULE X and More New Offerings from Sciton at ASLMShttps://practicaldermatology.com/news/meet-joule-x-and-more-new-offerings-from-sciton-at-aslms/2459954/Sciton Inc. unveiled JOULE X and other new offerings at the annual American Society for Laser Medicine and Surgery Meeting in Denver, Colorado. An upgrade to the JOULE platform, JOULE X is the company’s latest multi-device platform. It work
- Now Available: neuLASH Professional and neuBROW Professionalhttps://practicaldermatology.com/news/now-available-neulash-professional-and-neubrow-professional/2459956/New from Skin Research Professional and Olive and Delmar, neuLASH PROFESSIONAL™ and neuBROW PROFESSIONAL™ are available in all new, next-generation, professional-strength formulations. neuLASH PROFESSIONAL™ is a peptide serum promoting longer-looking lashes and neuBROW PROFESS
- Nextech Partners with RxPhoto for Integrated Image Managementhttps://practicaldermatology.com/news/nextech-partners-with-rxphoto-for-integrated-image-management/2459958/Nextech Systems has launched a new partnership with RxPhoto, a collaborative medical imagery solution. This partnership integrates RxPhoto’s patient photograph
- Biofrontera Reports Positive Phase 3 Results with Ameluz for PDT of AKs on Extremities and Trunk/Neckhttps://practicaldermatology.com/news/biofrontera-reports-positive-phase-3-results-with-ameluz-for-pdt-of-aks-on-extremities-and-trunkneck/2459961/Results for the primary endpoint of Biofrontera AG's Phase 3 clinical trial evaluating the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz and the BF-RhodoLED lamp for the treatment of actinic keratoses (AK) on the extremities as well as the trunk and neck are posti